Outcome and prognostic factors of relapsed/ refractory mature B cell non {u2013}Hodgkin Lymphoma at National Cancer Institute / Amany Hussein Abdelhafeiz ; Supervised Hany Abdelrahman Sayed , Sahar Ahmed Khalil , Ghada Mahmoud Sherif

By:

Amany Hussein Abdelhafeiz

Contributor(s):

Material type: Text

TextLanguage: English Publication details: Cairo : Amany Hussein Abdelhafeiz , 2017Description: 115 P. : charts , facsimiles ; 25cmOther title:

العوامل المؤثرة ونتائج سرطان الغدد الليمفاوىة في الخلايا البائية الناضجة المرتد والمقاوم للعلاج بالمعهد القومي للاورام [Added title page title]

Subject(s):

Available additional physical forms:

Issued also as CD

Dissertation note: Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology Summary: Background Mature B-cell non Hodgkin Lymphoma is the most common subtype of non-Hodgkin Lymphoma in pediatric age group. Although the survival of the patients had been significantly improved after treatment with multi agents, non-cross resistant chemotherapy over short time interval, the patients with relapsed/refractory disease have a dismal prognosis. Methods A retrospective cohort study reviewed all relapsed/refractory mature B-cell non Hodgkin Lymphoma patients under age of 18 years at diagnosis diagnose at National Cancer Institute, Cairo University, during the time period from January 2008 to end of December 2015. Results The incidence of relapsed/ refractory disease was (7.6 %) as there were 23 patients out of 303, with median age of 8 years, it showed male predominance with male to female ratio 1.9:1, 16 patients (69.6%) had Burkitt lymphoma and 7 patients (30.4%) had Burkitt leukemia. 14 patients (60.9%) were initially treated in risk group B, 9 patients (39.1%) were initially treated in risk group C.13 patients (56,5%) had relapse/progression in one site and 10 patients(43.5%) had relapse/progression in multiple sites. 22 patients (95,7%) received salvage chemotherapy and 4 patients achieved complete remission, all of them are alive and only one had stem cell transplantation. Conclusion: The incidence of relapse/refractory disease in patients with mature B cell non -Hodgkin lymphoma treated at National Cancer Institute during the time period from January 2008 to end of December 2015 was comparable to international results during the same period. Its outcome is very poor, approximately two thirds of mortalities were caused by infection raising the importance of infection control and strong supportive care measures for this patient population

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Home library	Call number	Copy number	Status	Date due	Barcode
Thesis	قاعة الرسائل الجامعية - الدور الاول	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.19.05.M.Sc.2017.Am.O (Browse shelf(Opens below))		Not for loan		01010110074619000
CD - Rom	مخـــزن الرســائل الجـــامعية - البدروم	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.19.05.M.Sc.2017.Am.O (Browse shelf(Opens below))	74619.CD	Not for loan		01020110074619000

Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology

Background Mature B-cell non Hodgkin Lymphoma is the most common subtype of non-Hodgkin Lymphoma in pediatric age group. Although the survival of the patients had been significantly improved after treatment with multi agents, non-cross resistant chemotherapy over short time interval, the patients with relapsed/refractory disease have a dismal prognosis. Methods A retrospective cohort study reviewed all relapsed/refractory mature B-cell non Hodgkin Lymphoma patients under age of 18 years at diagnosis diagnose at National Cancer Institute, Cairo University, during the time period from January 2008 to end of December 2015. Results The incidence of relapsed/ refractory disease was (7.6 %) as there were 23 patients out of 303, with median age of 8 years, it showed male predominance with male to female ratio 1.9:1, 16 patients (69.6%) had Burkitt lymphoma and 7 patients (30.4%) had Burkitt leukemia. 14 patients (60.9%) were initially treated in risk group B, 9 patients (39.1%) were initially treated in risk group C.13 patients (56,5%) had relapse/progression in one site and 10 patients(43.5%) had relapse/progression in multiple sites. 22 patients (95,7%) received salvage chemotherapy and 4 patients achieved complete remission, all of them are alive and only one had stem cell transplantation. Conclusion: The incidence of relapse/refractory disease in patients with mature B cell non -Hodgkin lymphoma treated at National Cancer Institute during the time period from January 2008 to end of December 2015 was comparable to international results during the same period. Its outcome is very poor, approximately two thirds of mortalities were caused by infection raising the importance of infection control and strong supportive care measures for this patient population

Issued also as CD

There are no comments on this title.

to post a comment.